Navigation Links
Hepatitis Awareness: Bringing Attention to a Silent Epidemic
Date:5/22/2013

ALEXANDRIA, Va., May 22, 2013 /PRNewswire/ -- Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. More than 75 percent of those with hepatitis C are unaware they have the virus.

Hepatitis B and C Testing and Awareness Day in the U.S. House of Representatives will take place at 10:00 am - 2:00 pm in the Rayburn Foyer of the Rayburn House Office Building in Washington, D.C.

The American Association for the Study of Liver Diseases (AASLD) is pleased to participate with the Congressional Hepatitis Caucus, the National Viral Hepatitis Roundtable, the Community Education Group, Hepatitis B Initiative of Washington DC, Caring Ambassadors Program, the National Alliance of State and Territorial AIDS Directors, the Association of Chinese American Physicians, and private industry to provide testing for hepatitis B and C.  

In May 2011, the United States Department of Health and Human Services (HHS) released "Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis." The plan runs through 2013, and AASLD -- the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease -- welcomes the HHS announcement that it intends to update and renew the plan for 2014-2016.

Access to care and support of liver disease research are at the center of AASLD's advocacy efforts and Hepatitis Awareness Month and hepatitis testing events are necessary to make Americans aware that they can now be tested and treated for hepatitis C.

Research in the area of hepatitis C has led to FDA approval of two direct acting antiviral drugs for the treatment of hepatitis C, and numerous other direct acting antiviral drugs are in the development pipeline. AASLD looks forward to -- and its members work diligently to realize -- the day when an all-oral, interferon-free, shortened treatment can be used to eradicate the virus from patients with hepatitis C.

As research in hepatitis C continues, the fight against hepatitis B does so too, and AASLD members are at the forefront of these battles. We are proud to partner with the Centers for Disease Control and Prevention and others at HHS wherever there is an opportunity to raise awareness of both hepatitis B and C.

  • May is Hepatitis Awareness Month.
  • May 2013 is the second anniversary of the National Viral Hepatitis Action Plan.
  • May 19, 2013, was the second annual Hepatitis Testing Day.
  • May 23, 2013, is Hepatitis B and C Testing and Awareness Day in the U.S. House of Representatives.

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.

Press releases and additional information about AASLD are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766
gbologna@aasld.org

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
2. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
3. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
4. The race toward an interferon free world: The current field of Hepatitis C Virus treatment research, including recent financial deals
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Aethlon Medical (AEMD) Note: New Government Contract, Resubmission of IDE to Treat Hepatitis C (HCV), Biothreat Legislation Signed into Law by President Obama
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Specialty drug costs account for more than 50 percent of the total cost of care for rheumatoid arthritis and hepatitis C patients
9. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
10. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
11. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... agreed to schedule an End-of-Phase II meeting with Oramed ... oral insulin capsule ORMD-0801 in the treatment of type ... secondary endpoints by indicating a statistically significant lowering of ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology:
(Date:7/26/2017)... , ... July 26, 2017 , ... An inventor from ... and I haven’t yet seen an effective and dignified way to keep leeches in ... the LEECH CUP." , This invention provides an effective way to keep a leech ...
(Date:7/26/2017)... Ca (PRWEB) , ... July 26, 2017 , ... A ... lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry cycle are ... webinar will discuss freeze drying techniques, as well as new accessories and advancements in ...
(Date:7/26/2017)... ... July 26, 2017 , ... GTB ... cloud ; today announced the availability of its latest data protection solution Crypt-n-Chive. ... control console for Data Discovery, Classification, Encryption and Digital Rights Management; GTB Crypt-n-Chive ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and ... from April 1, 2017 to June 30, 2017. Iso International LLC recorded unaudited ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... “Now Hiring!” ... St. Louis, Missouri. The company has achieved record-breaking sales for over 30 consecutive ... the next 12 months. , The upcoming year offers excitement and growth at HDIS, ...
Breaking Medicine News(10 mins):